|
66 Companies |
|
64 Products |
|
64 Products |
|
38 Mechanisms of Action |
|
0 Trials |
|
1523 News |
|
| «12345678910111213...3031» |
- Trial completion, Enrollment change: Immune Responses Induced by Different Licensed Influenza Vaccines (clinicaltrials.gov) - May 3, 2016
P=N/A, N=193, Completed, Sponsor: University of Massachusetts, Worcester
Active, not recruiting --> Completed | N=36 --> 193
- Enrollment change: Influenza Vaccine in Pregnancy Part 2 (clinicaltrials.gov) - Apr 26, 2016
P=N/A, N=100, Completed, Sponsor: St. Michael's Hospital, Toronto
Active, not recruiting --> Completed | N=36 --> 193 N=250 --> 100
- Enrollment open, Enrollment change, Trial primary completion date: VAX-002: Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics (clinicaltrials.gov) - Apr 26, 2016
P=N/A, N=50, Recruiting, Sponsor: Emory University
N=250 --> 100 Completed --> Recruiting | N=22 --> 50 | Trial primary completion date: Jul 2015 --> Jul 2017
- Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial primary completion date: Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults (clinicaltrials.gov) - Apr 21, 2016
P2, N=360, Active, not recruiting, Sponsor: University of Colorado, Denver
Completed --> Recruiting | N=22 --> 50 | Trial primary completion date: Jul 2015 --> Jul 2017 Trial primary completion date: Mar 2016 --> Sep 2015
- | Trial completion: Aerobic Exercise and Flu-like Symptoms Following Interferon Beta 1a Injections in Patients With Multiple Sclerosis? (clinicaltrials.gov) - Apr 19, 2016
P=N/A, N=20, Completed, Sponsor: University of Aarhus
Trial primary completion date: Mar 2016 --> Sep 2015 Active, not recruiting --> Completed
- paracetamol / Generic mfg., ibuprofen / Generic mfg.
Trial completion, Enrollment change: The Effect of Prophylactic Antipyretics on Immune Responses and Fever After 2014-2015 and 2015-2016 Inactivated Influenza Vaccine (clinicaltrials.gov) - Apr 7, 2016
P4, N=104, Completed, Sponsor: Duke University
Active, not recruiting --> Completed Recruiting --> Completed | N=160 --> 104
- Trial completion: Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors (clinicaltrials.gov) - Mar 31, 2016
P0, N=38, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Recruiting --> Completed | N=160 --> 104 Active, not recruiting --> Completed
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Trial primary completion date: Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults (clinicaltrials.gov) - Mar 18, 2016
P1, N=48, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial primary completion date: Mar 2014 --> Mar 2016
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
Enrollment closed, Trial primary completion date: Evaluating the Safety and Immunogenicity of a H7N9 Vaccine for the Prevention of Influenza H7N9 Disease in Adults 50 to 70 Years Old (clinicaltrials.gov) - Mar 18, 2016
P1, N=24, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Mar 2014 --> Mar 2016 Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> May 2016
- ||| oseltamivir / Generic mfg.
Trial completion, Enrollment change: IRIS: Influenza Resistance Information Study (clinicaltrials.gov) - Mar 17, 2016
P=N/A, N=4184, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | Trial primary completion date: May 2015 --> May 2016 Recruiting --> Completed | N=1200 --> 4184
- Trial completion: The Role of the Cervical Spine in Carpal Tunnel Syndrome (clinicaltrials.gov) - Mar 15, 2016
P=N/A, N=100, Completed, Sponsor: Universidad Rey Juan Carlos
Recruiting --> Completed | N=1200 --> 4184 Active, not recruiting --> Completed
- ||||||| Fluad Quadrivalent (inactivated quadrivalent influenza vaccine) / CSL Behring
Trial completion: Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05 (clinicaltrials.gov) - Mar 2, 2016
P3, N=1400, Completed, Sponsor: Novartis
Active, not recruiting --> Completed Active, not recruiting --> Completed
- FluMist (influenza vaccine, live, intranasal) / AstraZeneca, Fluzone (influenza vaccine) / Sanofi, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Trial completion, Enrollment change: Randomized Study of Immune Response to Licensed Influenza Vaccines in Children and Adolescents (clinicaltrials.gov) - Feb 27, 2016
P4, N=131, Completed, Sponsor: Marshfield Clinic Research Foundation
Active, not recruiting --> Completed Enrolling by invitation --> Completed | N=180 --> 131
- | M-001 / BiondVax
Trial completion: Phase II Study to Assess Safety & Immunogenicity of Multimeric-001 Influenza Vaccine, Followed by TIV (clinicaltrials.gov) - Feb 23, 2016
P2, N=37, Completed, Sponsor: BiondVax Pharmaceuticals ltd.
Enrolling by invitation --> Completed | N=180 --> 131 Recruiting --> Completed
- ||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Enrollment change: DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants (clinicaltrials.gov) - Feb 18, 2016
P3, N=310, Active, not recruiting, Sponsor: Sanofi Pasteur, a Sanofi Company
Recruiting --> Completed N=458 --> 310
- Trial completion, Trial primary completion date: Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03) (clinicaltrials.gov) - Feb 16, 2016
P2, N=50, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=458 --> 310 Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Feb 2015
- || Rebif (human IFN-β-1a) / EMD Serono
Trial primary completion date: RELIEF: A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis (clinicaltrials.gov) - Feb 12, 2016
P4, N=218, Recruiting, Sponsor: Merck KGaA
Active, not recruiting --> Completed | Trial primary completion date: Apr 2014 --> Feb 2015 Trial primary completion date: Dec 2015 --> Apr 2016
- Trial completion, Enrollment change, Trial primary completion date: Immune Response to Seasonal Influenza Vaccine in HIV Infected Individuals (clinicaltrials.gov) - Feb 10, 2016
P=N/A, N=74, Completed, Sponsor: George Washington University
Trial primary completion date: Dec 2015 --> Apr 2016 Active, not recruiting --> Completed | N=100 --> 74 | Trial primary completion date: Jun 2016 --> Aug 2014
- Trial primary completion date: Micronutrient Supplementation and Incidence of Common Cold (clinicaltrials.gov) - Feb 10, 2016
P=N/A, N=82, Active, not recruiting, Sponsor: Green Beat
Active, not recruiting --> Completed | N=100 --> 74 | Trial primary completion date: Jun 2016 --> Aug 2014 Trial primary completion date: Oct 2015 --> Oct 2016
- Trial completion: Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine (clinicaltrials.gov) - Feb 9, 2016
P1, N=69, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Oct 2015 --> Oct 2016 Active, not recruiting --> Completed
- Trial primary completion date: Use of Probiotics to Prevent Influenza (clinicaltrials.gov) - Feb 4, 2016
P=N/A, N=1440, Recruiting, Sponsor: McMaster University
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- Trial primary completion date: SCID Bu/Flu/ATG Study With T Cell Depletion (clinicaltrials.gov) - Feb 3, 2016
P1/2, N=15, Enrolling by invitation, Sponsor: Neena Kapoor, M.D.
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Dec 2016
- || Trial primary completion date, Combination therapy: A Study of MHAA4549A in Combination With Oseltamivir Versus Oseltamivir in Participants With Severe Influenza A Infection (clinicaltrials.gov) - Feb 2, 2016
P2, N=330, Recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Feb 2017 --> Jun 2017
- Trial primary completion date: Anti-inflammatory Effects of Macrolide Treatment in Influenza Lower Respiratory Tract Infections (clinicaltrials.gov) - Jan 28, 2016
P4, N=100, Recruiting, Sponsor: Chinese University of Hong Kong
Trial primary completion date: Feb 2017 --> Jun 2017 Trial primary completion date: Dec 2015 --> Jun 2016
- Trial completion: PregText: Feasibility of Monitoring Influenza Vaccine Safety in Pregnant Women Using Text Messaging (clinicaltrials.gov) - Jan 28, 2016
P=N/A, N=166, Completed, Sponsor: Columbia University
Trial primary completion date: Dec 2015 --> Jun 2016 Active, not recruiting --> Completed
- Trial completion: eX-FLU: A Study of Exclusion Criteria in a University Population (clinicaltrials.gov) - Jan 27, 2016
P=N/A, N=1400, Completed, Sponsor: University of Michigan
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: VAX-002: Systems Biology of Flu Vaccine in Healthy Adults With and Without the Use of Antibiotics (clinicaltrials.gov) - Jan 21, 2016
P=N/A, N=22, Completed, Sponsor: Emory University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial primary completion date: Study of the Immune Response After Vaccination in Multiple Myeloma Patients (clinicaltrials.gov) - Jan 18, 2016
P=N/A, N=80, Recruiting, Sponsor: Michael A. Thompson, MD, PhD
Active, not recruiting --> Completed Trial primary completion date: Dec 2015 --> Dec 2016
- Trial primary completion date: Influenza Immunization of Children in India (clinicaltrials.gov) - Jan 18, 2016
P4, N=3600, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: Dec 2015 --> Mar 2016
- Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial primary completion date: Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults (clinicaltrials.gov) - Jan 17, 2016
P2, N=360, Active, not recruiting, Sponsor: University of Colorado, Denver
Trial primary completion date: Dec 2015 --> Mar 2016 Trial primary completion date: Dec 2015 --> Mar 2016
- Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Enrollment closed, Enrollment change: A Pilot Study to Assess the Immunogenicity and Reactogenicity of High Versus Standard Dose TIV (clinicaltrials.gov) - Jan 15, 2016
P1/2, N=170, Active, not recruiting, Sponsor: Mount Sinai Hospital, Canada
Trial primary completion date: Dec 2015 --> Mar 2016 Recruiting --> Active, not recruiting | N=100 --> 170
- Trial completion, Enrollment change: Do Some Healthy Adults Consistently Have Systemic Reactions to Influenza Vaccines? (clinicaltrials.gov) - Jan 15, 2016
P4, N=11, Completed, Sponsor: Mount Sinai Hospital, Canada
Recruiting --> Active, not recruiting | N=100 --> 170 Recruiting --> Completed | N=35 --> 11
- Trial completion: MOTIVATE: Mail Outreach To Increase Vaccination Acceptance Through Engagement (clinicaltrials.gov) - Jan 12, 2016
P=N/A, N=228000, Completed, Sponsor: Brigham and Women's Hospital
Recruiting --> Completed | N=35 --> 11 Not yet recruiting --> Completed
- ||||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
Trial completion: Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (clinicaltrials.gov) - Jan 6, 2016
P3, N=558, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Not yet recruiting --> Completed Active, not recruiting --> Completed
- ||| Trial completion, Trial primary completion date: Residual Sample Collection for Respiratory Viral Panel (clinicaltrials.gov) - Dec 29, 2015
P=N/A, N=1487, Completed, Sponsor: GenMark Diagnostics
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Aug 2015 --> Nov 2015
- Fluvirin (inactivated influenza virus vaccine) / CSL Behring, Fluzone (influenza vaccine) / Sanofi
Phase classification: High-Dose Trivalent Influenza Vaccine in Inducing Immune Response Patients With Central Nervous System Tumors (clinicaltrials.gov) - Dec 29, 2015
P1, N=60, Active, not recruiting, Sponsor: Comprehensive Cancer Center of Wake Forest University
Recruiting --> Completed | Trial primary completion date: Aug 2015 --> Nov 2015 Phase classification: P=N/A --> P1
- Enrollment change: Fever and Wheezing Events in Children After US Influenza Vaccines Using Text Messaging (clinicaltrials.gov) - Dec 25, 2015
P=N/A, N=275, Recruiting, Sponsor: Columbia University
Phase classification: P=N/A --> P1 N=150 --> 275
- Enrollment change, Trial termination: Vitamin D Supplementation and the Immune Response (clinicaltrials.gov) - Dec 23, 2015
P2, N=37, Terminated, Sponsor: University Hospital, Clermont-Ferrand
N=150 --> 275 N=188 --> 37 | Recruiting --> Terminated
- Trial completion: AIMHi: Testing the Use of Prompts to Increase Adolescent Immunization Rates (clinicaltrials.gov) - Dec 17, 2015
P=N/A, N=7040, Completed, Sponsor: University of California, Los Angeles
N=188 --> 37 | Recruiting --> Terminated Active, not recruiting --> Completed
- Clinical: Blood and Plasma Collection For Use in Future Clinical Trials (clinicaltrials.gov) - Dec 16, 2015
P=N/A, N=200, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial primary completion date: Apr 2015 --> Apr 2016
- Trial completion, Trial primary completion date: IRC002: Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza (clinicaltrials.gov) - Dec 16, 2015
P2, N=150, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial primary completion date: Apr 2015 --> Apr 2016 Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Mar 2015
- FluMist (influenza vaccine, live, intranasal) / AstraZeneca, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Biomarker, Trial completion, Trial primary completion date: Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines (clinicaltrials.gov) - Dec 15, 2015
P1, N=36, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed | Trial primary completion date: Oct 2015 --> Mar 2015 Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jun 2013
- Trial completion, Trial primary completion date: Evaluating the Safety and Immune Response of an H7N7 Vaccine in Healthy Adults (clinicaltrials.gov) - Dec 15, 2015
P1, N=45, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed | Trial primary completion date: Dec 2014 --> Jun 2013 Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Mar 2014
- Trial completion: A Phase I Study of Candidate Influenza Vaccines MVA-NP+M1 and ChAdOx1 NP+M1 (clinicaltrials.gov) - Dec 15, 2015
P1, N=72, Completed, Sponsor: University of Oxford
Active, not recruiting --> Completed | Trial primary completion date: Jun 2015 --> Mar 2014 Active, not recruiting --> Completed
- ||| Ampligen (rintatolimod) / AIM ImmunoTech
Enrollment closed: Safety Study of FluMist With and Without Ampligen (clinicaltrials.gov) - Dec 9, 2015
P1/2, N=72, Active, not recruiting, Sponsor: Hemispherx Biopharma
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||| Trial completion: Safety and Immunogenicity of Different Formulations of an Adjuvanted, Trivalent Subunit Influenza Vaccine in Elderly Subjects 65 Years of Age and Above (clinicaltrials.gov) - Dec 9, 2015
P1, N=196, Completed, Sponsor: Novartis
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||||| Plegridy (PEG-interferon ?-1a) / Biogen
Trial completion: Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-?) Therapies to Peginterferon Beta-1a (BIIB017) (clinicaltrials.gov) - Dec 5, 2015
P3, N=201, Completed, Sponsor: Biogen
Active, not recruiting --> Completed Active, not recruiting --> Completed
- amantadine / Generic mfg.
Trial primary completion date: IRC003: Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the Treatment of Influenza in Adults at Risk for Complications (clinicaltrials.gov) - Dec 5, 2015
P2, N=1200, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Trial primary completion date: Sep 2015 --> Sep 2016
- Trial primary completion date: Respiratory Virus Outpatient Study (FLU 002 Plus) (clinicaltrials.gov) - Dec 5, 2015
P=N/A, N=5000, Recruiting, Sponsor: University of Minnesota - Clinical and Translational Science Institute
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: Aug 2015 --> Aug 2016
- oseltamivir / Generic mfg.
Trial primary completion date: Rapid Empiric Treatment With Oseltamivir Study (RETOS) (clinicaltrials.gov) - Dec 5, 2015
P4, N=1000, Enrolling by invitation, Sponsor: University of Louisville
Trial primary completion date: Aug 2015 --> Aug 2016 Trial primary completion date: May 2015 --> May 2016